Stem cells for the treatment of liver disease.
Stem cells tantalise. They alone have the capacity to divide exponentially, recreate the stem cell compartment as well as create differentiated cells to build tissues. They should be the natural candidates to provide a renewable source of cells for transplantation. Does the reality support the promise of this exciting alternative to conventional therapies for metabolic and degenerative liver disease? Can techniques be developed to provide the large number of cells that could be required? Must there be "space" in the liver to accept the cells? To what extent is the liver immunoprivileged, and is immunosuppression necessary for stem cell therapy? Is it better to use haematopoietic stem cells, fetal stem cells, mesenchymal cells, embryonic stem cells, hepatocytes or all of the above, but for different disease indications? This paper discusses why the exploration of stem cells for the treatment of liver disease is of great potential, and delineates some of the hurdles that need to be overcome before patients see benefits from laboratory-based research into stem cell transplantation and function.
Allen
K J
KJ
Liver Research Group, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Victoria 3052, Australia. katie.allen@rch.org.au
Buck
N E
NE
Williamson
R
R
D000818:Animals; D002986:Clinical Trials as Topic; D053595:Embryonic Stem Cells / Q000637:transplantation; D006801:Humans; D008107:Liver Diseases / Q000628:therapy*; D033581:Stem Cell Transplantation / Q000379:methods* / Q000639:trends